Design, power, and alpha levels in randomized phase II oncology trials

BACKGROUND: The statistical plan of a phase II trial should balance minimizing the premature termination of potentially beneficial therapies (i.e. false negatives) and the further, costly testing of ineffective drugs (i.e. false positives). We sought to examine the methodology, reporting, and bias i...

Descripción completa

Detalles Bibliográficos
Autores principales: Haslam, A., Olivier, T., Prasad, V.
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Elsevier 2023
Materias:
Original Research
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10024120/
https://www.ncbi.nlm.nih.gov/pubmed/36736072
http://dx.doi.org/10.1016/j.esmoop.2022.100779

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10024120/
https://www.ncbi.nlm.nih.gov/pubmed/36736072
http://dx.doi.org/10.1016/j.esmoop.2022.100779

Ejemplares similares